NCT03977194

Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Phase III Randomized Trial of Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Monthly Carboplatin With Weekly Paclitaxel Chemotherapy

• Status: Active Not Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 510 (actual)
• Sponsor: Intergroupe Francophone de Cancerologie Thoracique · Academic / Other
• Sex: All
• Age: 70 Years – 89 Years
• Healthy volunteers: Not accepted

Summary

Non Small Cell Lung Cancer (NSCLC) remains the leading cause of death by cancer in the world. Because of the increase in lung cancer incidence with age and the increase of life expectancy, about half of the patients are patients aged 70 or older. Several clinical trials have shown the interest of adding immunotherapy to standard 1st line chemotherapy in NSCLC. Although in these studies there was not necessarily a higher age limit, in fact the proportion of included patients aged 75 or older remains low (between 7 and 10%). It is therefore necessary to conduct a trial dedicated to these patients in order to determine whether immunotherapy is as effective and tolerated as in the general population.

Conditions

• Non Small Cell Lung Cancer Metastatic

Interventions

Type	Name	Description
DRUG	Carboplatin	AUC 6 every 4 weeks
DRUG	Paclitaxel	90 mg/m² D1, 8, 15, every 4 weeks
DRUG	Atezolizumab	1200 mg every 3 weeks

Timeline

• Start date: 2019-07-23
• Primary completion: 2024-08-31
• Completion: 2026-12-01
• First posted: 2019-06-06
• Last updated: 2025-11-18

Locations

68 sites across 1 country: France